Other disadvantages include the fact that hereditary AIDs can be more difficult to treat than inflammatory diseases such as rheumatoid arthritis, and there are safety and medical-economic issues with the long-term administration of IL-6 inhibitors. The gene discussed is IL6; the disease is rheumatoid arthritis.